{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11(1)"],"submitter":["Tukhvatulin AI"],"funding":["Russain Direct Investment Fund"],"pubmed_abstract":["Although unprecedented efforts aiming to stop the COVID-19 pandemic have been made over the past two years, SARSCoV-2 virus still continues to cause intolerable health and economical losses. Vaccines are considered the most effective way to prevent infectious diseases, which has been reaffirmed for COVID-19. However, in the context of the continuing virus spread because of insufficient vaccination coverage and emergence of new variants of concern, there is a high demand for vaccination strategy amendment. The ability to elicit protective immunity at the entry gates of infection provided by mucosal vaccination is key to block virus infection and transmission. Therefore, these mucosal vaccines are believed to be a \"silver bullet\" that could bring the pandemic to an end. Here, we demonstrate "],"journal":["Emerging microbes & infections"],"pagination":["2229-2247"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9518644"],"repository":["biostudies-literature"],"pubmed_title":["Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates."],"pmcid":["PMC9518644"],"pubmed_authors":["Naroditsky BS","Logunov DY","Kovyrshina AV","Zorkov ID","Grousova DM","Zubkova OV","Tokarskaya EA","Esmagambetov IB","Illarionova VV","Savina DM","Ungur AS","Shelkov AY","Bayurova EO","Vereveyko YR","Tukhvatulin AI","Shcheblyakov DV","Iliukhina AA","Erokhova AS","Ishmukhametov AA","Dolzhikova IV","Botikov AG","Kondrashova AS","Moroz AV","Gintsburg AL","Gordeychuk IV","Avdoshina DV","Gulyaeva TV","Krasina ME","Gulyaev SA","Dzharullaeva AS"],"additional_accession":[]},"is_claimable":false,"name":"Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates.","description":"Although unprecedented efforts aiming to stop the COVID-19 pandemic have been made over the past two years, SARSCoV-2 virus still continues to cause intolerable health and economical losses. Vaccines are considered the most effective way to prevent infectious diseases, which has been reaffirmed for COVID-19. However, in the context of the continuing virus spread because of insufficient vaccination coverage and emergence of new variants of concern, there is a high demand for vaccination strategy amendment. The ability to elicit protective immunity at the entry gates of infection provided by mucosal vaccination is key to block virus infection and transmission. Therefore, these mucosal vaccines are believed to be a \"silver bullet\" that could bring the pandemic to an end. Here, we demonstrate ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2026-05-28T00:35:24.704Z","creation":"2025-04-19T05:18:27.383Z"},"accession":"S-EPMC9518644","cross_references":{"pubmed":["36031930"],"doi":["10.1080/22221751.2022.2119169"]}}